FDA Rejection Triggers Sharp Selloff and Legal Action
Corcept Therapeutics Incorporated ($CORT) has become the subject of a securities class action lawsuit following a devastating regulatory setback that wiped roughly half the company's stock value in a single trading session. On December 31, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for relacorilant, the company's lead drug candidate, citing insufficient evidence of effectiveness to support approval. The regulatory rejection triggered an immediate and severe market reaction, with $CORT shares plummeting 50.4% from $70.20 to $34.80, representing a catastrophic loss for shareholders who held positions during this period.
The lawsuit, being administered by the prominent securities litigation firm Kahn Swick & Foti, LLC, targets the company and its executives for allegedly failing to disclose material information about the drug's efficacy challenges to investors. Shareholders who purchased $CORT shares between October 31, 2024 and December 30, 2025—the period spanning the apparent concealment of regulatory risks—are eligible to participate in the action. The deadline for filing lead plaintiff applications is April 21, 2026, giving investors a window of opportunity to seek recovery for their losses.
The Regulatory Stumble and Its Market Consequences
The Complete Response Letter represents one of the most significant regulatory disappointments in Corcept's recent history and raises fundamental questions about the company's drug development pipeline and clinical trial design. Rather than approving relacorilant for commercial use, the FDA determined that the evidence presented was insufficient to demonstrate the drug's effectiveness in treating its intended indication—a verdict that invalidates years of development effort and substantial capital investment.
Key factors surrounding the rejection include:
- Timing: The FDA's decision arrived on the final day of 2025, immediately before the New Year holiday, which typically amplifies market impact as investors process negative news with limited trading activity
- Stock performance: The 50.4% decline reflects not just the loss of a single asset but broader investor concern about Corcept's pipeline depth and future prospects
- Market capitalization destruction: The sharp sell-off eliminated billions in shareholder value in hours
- Disclosure allegations: The securities lawsuit implies that Corcept possessed knowledge of efficacy concerns that were not adequately communicated to the investment community
The Complete Response Letter mechanism, while not as final as an outright rejection, effectively halts the commercialization pathway unless the company can address the FDA's specific concerns through additional clinical trials or data reanalysis—a process that typically requires 12-24 months and substantial additional investment.
Market Context: Biotech Volatility and Regulatory Risk
The $CORT collapse illustrates the inherent risks of biotech investment, where regulatory decisions can instantly erase shareholder value regardless of underlying fundamentals or historical performance. For a company that had traded at $70.20 just weeks earlier, the abrupt rejection exposed how concentrated risk becomes when a pipeline depends heavily on a single therapeutic candidate.
Corcept Therapeutics, founded in 1998, has historically focused on cortisol-related disorders and the Cushing syndrome market. Relacorilant represented a significant advancement in the company's portfolio and was positioned as a major commercial opportunity. The FDA's determination that clinical evidence failed to meet approval standards suggests either that the clinical trial design was insufficient, the patient population results were underwhelming, or that safety concerns emerged during review.
The biotech sector has faced increased regulatory scrutiny in recent years, with the FDA maintaining elevated evidentiary standards for drug approvals. Competitors and investors in similar companies may now face heightened concern regarding their own clinical programs, particularly those involving psychiatric or endocrine conditions where efficacy endpoints can be subjective or difficult to measure.
Investor Implications and Legal Recourse
For shareholders, the securities class action represents a potential avenue for recovering losses, though litigation success is never assured. The lawsuit's viability depends on proving that Corcept made material misstatements or omissions regarding relacorilant's regulatory prospects during the relevant period. If the company downplayed efficacy concerns, assured investors of regulatory pathway clarity, or failed to disclose known clinical trial challenges, shareholders may have grounds for recovery through settlement or judgment.
The April 21, 2026 lead plaintiff deadline is critical for investors seeking to direct the litigation strategy. Lead plaintiffs typically receive some preference in recovery distribution and may negotiate class settlement terms. Shareholders should:
- Gather documentation of their $CORT purchases between October 31, 2024 and December 30, 2025
- Document the timing and value of their losses
- Contact qualified securities counsel to evaluate eligibility
- Monitor filings with the appropriate federal court for additional case developments
The broader implications extend to Corcept's long-term viability and shareholder confidence. Without relacorilant, the company must demonstrate that its existing product portfolio and alternative pipeline candidates can generate sufficient revenue to support operations and future R&D investment. This regulatory setback may also impair the company's ability to access capital markets for financing, as institutional investors become more cautious about pipeline risk.
Looking Forward: Regulatory and Strategic Uncertainty
The path forward for Corcept remains uncertain. The company can attempt to address the FDA's specific concerns, resubmit additional data, or pursue meetings with regulators to clarify what evidence gaps need to be filled. However, each alternative demands both time and capital—resources that become scarcer as shareholder confidence erodes and stock price remains depressed.
For the broader investment community, the $CORT situation serves as a reminder that regulatory risk in biotech cannot be hedged away through diversification alone. A single FDA decision can reshape investment thesis and destroy shareholder value in minutes. As the securities class action moves forward, investors eligible to participate should act promptly to protect their legal interests while the litigation framework is established.